hypoglycemia

Gatifloxacin (CG5501) is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial enzymes DNA gyrase and topoisomerase IV.

Gatifloxacin hydrochloride (AM-1155 hydrochloride) is a fourth-generation fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV.

AZD-1656 is a glucokinase activator (GKA) that can cause dose-limiting hypoglycemia in normal animals used in embryofetal development studies and type 2 diabetes.

Bruceine E is isolated from B. javanica seeds with hypoglycemia effects. Bruceine E can be used for studies about acting as an insulin secretagogue.

PF-04937319 is an activator of glucokinase (EC50 =154.4  μM). PF-04937319 maintains glucose-lowering efficacy while mitigating the risk of hypoglycemia observed with many other glucokinase activators. PF-04937319 can be used in research on the treatment of type 2 diabetes mellitus.

Risarestat (CT-112) is a potent aldose reductase inhibitor and thyroid hormone receptor (TR) antagonist for the treatment of hypoglycemia.

Sari 59-801 is a novel, orally effective hypoglycemic compound.

Imapextide is a glucagon-like peptide-1 (GLP-1) receptor antagonist used in hypoglycemia research.

CP-316819 (GPi 819) is a potent inhibitor of glycogen phosphorylase (GPase) with hypoglycemic effects, inhibits huSMGPa and huLGPa, maintains neuronal activity during hypoglycemia, and can be used in the study of hyperglycemia.

Rubratoxin B is a mycotoxin that causes hypoglycemia and fatty liver and has exhibited anticancer activity.

AZD-6370 is a glucokinase activator. AZD-6370 decreases fasting and postprandial glucose in type 2 diabetes mellitus patients with effects influenced by dosing regimen and food. AZD-6370 do not affect the central counterregulatory response to hypoglycemia

BMS-986118 is a full agonist of GPR40, is a G-protein-coupled receptor expressed primarily in pancreatic islets and intestinal L-cells that has been a target of significant recent therapeutic interest for type II diabetes. Activation of GPR40 by partial a

Sodium ethyl oxalacetate can be used in the treatment of hypoglycemia and ketonemia in the ruminant.

Octanoic Acid-13C is intended for use as an internal standard for the quantification of Octanoic Acid (T3946) by GC- or LC-MS. Octanoic acid is a medium-chain saturated fatty acid. It has been found in Teleme cheeses made from goat, ovine, or bovine milk.1 Octanoic acid is active against the bacteria S. mutans, S. gordonii, F. nucleatum, and P. gingivalis (IC80s = <125, <125, 1,403, and 2,294 μM, respectively).2 Levels of octanoic acid are increased in the plasma of patients with medium-chain acyl-CoA dehydrogenase (MCAD) deficiency, an inborn error of fatty acid metabolism characterized by hypoketotic hypoglycemia, medium-chain dicarboxylic aciduria, and intolerance to fasting.3,4

KQMEEEAVRLFIEWLKNGGPSSGAPPPS is a Exendin-4 peptide derivative. Exendin-4 is a pure GLP-1 receptor agonist. Exendin-4 peptide derivatives are structurally derived from Exendin-4 and may relates to dual GLP-1/glucagon receptor agonists. Their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake. These dual GLP-1/glucagon receptor agonists show reduced activity on the GIP receptor to reduce the risk of hypoglycemia[1]. [1]. US20150315260 A1

Paulownin, a furofuran lignan from Paulownia tomentosa,has the action of anti-inflammation,analgesia,immunity,hypoglycemia and has little toxicity.

Volagidemab (AMG-477) is a glucagon receptor (GCGR) antagonist and monoclonal antibody for the study of endocrine and metabolic diseases such as type 1 diabetes (T1D) and hypoglycemia.

Dasiglucagon acetate is a novel glucagon analog for diabetic hypoglycemia therapy. Dasiglucagon acetate has demonstrated established solubility and stability in an aqueous formulation. Pharmacokinetics studies have shown dasiglucagon acetate to exhibit hi

XOMA 129 is a human monoclonal antibody that targets the insulin receptor (INSR). This compound acts as an antagonist to the insulin receptor (IR), effectively inhibiting the decrease of blood glucose levels. XOMA 129 is applicable in the research of hypoglycemia.

Ersodetug (RZ358) is a fully human monoclonal antibody that targets an allosteric site on the insulin receptor (IR). As a negative modulator of insulin receptor activity, it effectively counteracts refractory hypoglycemia caused by insulin oversecretion, demonstrating significant potential in the study of congenital hyperinsulinism.

Serpentine is an alkaloid found in the roots of Rosa Centifolia that acts as an insulin sensitizer to assist insulin in lowering blood glucose.Serpentine activates the phosphorylation of AMPK, which stimulates glucose uptake by C2C12 cells.Serpentine increases the expression of GSK-3β mRNA in muscle tissues, which enhances glucose uptake.Serpentine also increases glucose production and hepatic gluconeogenesis.Serpentine has a significant effect on glucagon secretion and hepatic gluconeogenesis. Serpentine significantly increased glucagon secretion and hepatic gluconeogenesis. In high-fat diet/streptozotocin (HFD/STZ)-induced diabetic mice, Serpentine significantly prolonged insulin hypoglycemia, significantly decreased exogenous insulin use, and inhibited endogenous insulin secretion.

Avexitide acetate (exendin 9-39) is a potent glucagon-like peptide 1 receptor (GLP-1R) antagonist for the study of post-obesity hypoglycemia.

GHRF, ovine, is a growth hormone-releasing factor that specifically mediates the effects of hypoglycemia on the release of pituitary growth hormone (GH) [1].